|
|
|
Volumn 26, Issue 1 SUPPL. 2, 1999, Pages 129-133
|
|
The evolving role of paclitaxel for patients with carcinoma of unknown primary site
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBOPLATIN;
CIMETIDINE;
CISPLATIN;
DIPHENHYDRAMINE;
ETOPOSIDE;
PACLITAXEL;
ADENOCARCINOMA;
ANTINEOPLASTIC ACTIVITY;
BONE MARROW SUPPRESSION;
CANCER COMBINATION CHEMOTHERAPY;
CARCINOMA;
CLINICAL TRIAL;
CONFERENCE PAPER;
DRUG EFFICACY;
FEMALE;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
LEUKOPENIA;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
NEUROENDOCRINE TUMOR;
ORAL DRUG ADMINISTRATION;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
SQUAMOUS CELL CARCINOMA;
TUMOR DIFFERENTIATION;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
CLINICAL TRIALS;
ETOPOSIDE;
HUMANS;
NEOPLASMS, UNKNOWN PRIMARY;
PACLITAXEL;
|
|
EID: 0033036295
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (15)
|
|
References (14)
|
